5 terminated, 3 completed, 1 unknown. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 4, Completed 2, Unknown 1 |
| Phase 1 | 4 | Terminated 3, Completed 1 |
Follow tomivosertib: new trials by email Literature Review of tomivosertib trials Research Report on tomivosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Biospecimen Collection, Tomivosertib - Acute Myeloid Leukemia | Phase 1 | Terminated | Northwestern University | 8 | 2023-09-29 | 2026-06-11 |
| Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) Tomivosertib, Pembrolizumab, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Unknown | Effector Therapeutics | 68 | 2021-06-02 | 2024-04-30 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer tomivosertib, paclitaxel - Breast Cancer | Phase 1 | Completed | Translational Research in Oncology | 19 | 2020-08-25 | 2022-07-20 |
| An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer eFT508 - Castrate-resistant Prostate Cancer (CRPC) | Phase 2 | Terminated | Effector Therapeutics | 16 | 2018-11-27 | 2024-06-21 |
| Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy Tomivosertib (eFT-508) - Solid Tumors | Phase 2 | Completed | Effector Therapeutics | 39 | 2018-07-25 | 2023-03-22 |
| A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC eFT508 - Triple Negative Breast Cancer, Hepatocellular Carcinoma | Phase 2 | Terminated | Effector Therapeutics | 3 | 2017-11-21 | 2019-07-18 |
| A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer eFT508, Avelumab - Microsatellite Stable Relapsed or Refractory Colorectal Cancer | Phase 2 | Completed | Effector Therapeutics | 56 | 2017-09-18 | 2019-07-18 |
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies Tomivosertib (eFT-508) - Lymphoma | Phase 1 / Phase 2 | Terminated | Effector Therapeutics | 28 | 2017-02-08 | 2020-11-02 |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors eFT508 - Cancer | Phase 1 / Phase 2 | Terminated | Effector Therapeutics | 66 | 2015-12-03 | 2020-11-02 |
Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Melanoma (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Thyroid Diseases (1) · Triple Negative Breast Neoplasms (1)
Effector Therapeutics (7) · Northwestern University (1) · Translational Research in Oncology (1)
United States (8) · Australia (1) · Canada (1) · Georgia (1)
Jeremy Barton, MD (4) · Douglas Warner, MD (1) · Lyon Gleich, MD (1) · Lyon Gliech, MD (1) · Michael Pollak, MD (1) · Shira N Dinner (1)
P30CA060553 (1)